Of notable interest is a transgenic mouse model where the HCRT promoter drives a form of ataxin-3 containing a large polyglutamine repeat, resulting in HCRT cell death and a narcolepsy-like phenotype at 2–3 weeks of age [6]. The gene discussed is HCRT; the disease is narcolepsy.